10/18/2024

Janusmed sex and gender

Janusmed sex and gender – medroxyprogesterone

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Medroxyprogesterone

Medroxyprogesterone

Class : B

Show all info

Print

Contact us

  1. Fass.se för vårdpersonal

  2. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-05-23].

  3. Cross BS, DeYoung GR, Furmaga KM. High-dose oral medroxyprogesterone for inappropriate hypersexuality in elderly men with dementia: a case series. Ann Pharmacother. 2013;47:e1.

  4. Soufir JC, Meduri G, Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod. 2011;26:1708-14.

  5. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147-54.

  6. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64 Suppl 2:31-6.

  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-06-20.]

  1. Fass.se för vårdpersonal
  2. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-05-23].
  3. Cross BS, DeYoung GR, Furmaga KM. High-dose oral medroxyprogesterone for inappropriate hypersexuality in elderly men with dementia: a case series. Ann Pharmacother. 2013;47:e1.
  4. Soufir JC, Meduri G, Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod. 2011;26:1708-14.
  5. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147-54.
  6. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64 Suppl 2:31-6.
  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-06-20.]